Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children - Archive ouverte HAL Access content directly
Journal Articles Journal of Allergy and Clinical Immunology Year : 2016

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children

Darragh Duffy
Bruno Charbit
Anne Hulin
Nihel Khoudour

Dates and versions

hal-01911048 , version 1 (02-11-2018)

Identifiers

Cite

Marie-Louise Frémond, Mathieu Paul Rodero, Nadia Jeremiah, Alexandre Belot, Eric Jeziorski, et al.. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. Journal of Allergy and Clinical Immunology, 2016, 138 (6), pp.1752-1755. ⟨10.1016/j.jaci.2016.07.015⟩. ⟨hal-01911048⟩
93 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More